Examkin

Question

Difficulty: MediumInfectious Diseases

An internal medicine team evaluates a patient ready for transfer out of the acute care unit. The patient, a resident of an assisted living facility, presented 72 hours ago with profound chills, vomiting, and right-sided back pain. She was hemodynamically stable but highly symptomatic, prompting the initiation of empiric intravenous piperacillin-tazobactam. Currently, she has been afebrile for 24 hours, her vital signs are within normal limits, and she is comfortably eating a regular diet. Microbiological analysis of both blood and urine samples collected on admission reveals heavy growth (>105 CFU/mL>10^5 \text{ CFU/mL}) of *Enterococcus faecalis*. Susceptibility testing confirms the isolate is susceptible to ampicillin, amoxicillin, vancomycin, and nitrofurantoin. Which of the following is the most appropriate next step in pharmacotherapy?

  1. A
    Initiate oral nitrofurantoin therapy
  2. B
    Initiate oral ciprofloxacin therapy
  3. C
    Continue intravenous piperacillin-tazobactam therapy
  4. Initiate oral amoxicillin therapyAnswer
  5. E
    Switch to intravenous vancomycin therapy

Answer

The most appropriate step is to initiate oral amoxicillin therapy.
The correct answer is to initiate oral amoxicillin therapy. This patient presented with acute pyelonephritis complicated by bacteremia caused by *Enterococcus faecalis*. She is now clinically stable, afebrile, and tolerating oral intake, which are the core clinical criteria for stepping down from intravenous to oral antimicrobial therapy. *E. faecalis* is typically highly susceptible to aminopenicillins. Oral amoxicillin has excellent gastrointestinal absorption and achieves high therapeutic concentrations in both the bloodstream and the renal parenchyma. De-escalating from empiric broad-spectrum piperacillin-tazobactam to targeted oral amoxicillin demonstrates excellent antimicrobial stewardship while facilitating hospital discharge.

Step-by-Step Solution

1
Identify the patient's current clinical status and primary diagnosis.
The patient has acute pyelonephritis with associated bacteremia, but is now hemodynamically stable, afebrile, and successfully tolerating oral intake.
Determining clinical stability dictates whether empiric intravenous therapy can be safely transitioned to targeted oral therapy.
2
Analyze the microbiological data and susceptibility results.
Blood and urine cultures grew Enterococcus faecalis that is susceptible to ampicillin, amoxicillin, nitrofurantoin, and vancomycin.
Pathogen identification and in vitro susceptibility guide the selection of a definitive antimicrobial agent.
3
Rule out inappropriate agents based on pharmacokinetics.
Nitrofurantoin is rejected despite in vitro susceptibility.
Nitrofurantoin does not penetrate the renal parenchyma or bloodstream, making it ineffective and contraindicated for pyelonephritis and bacteremia.
4
Apply antimicrobial stewardship principles to select the optimal definitive therapy.
Oral amoxicillin is chosen as the final regimen.
Proper stewardship requires de-escalating to the narrowest effective agent. Amoxicillin targets the pathogen effectively, achieves high levels in the blood and renal tissue, and avoids the unnecessary use of broad-spectrum or intravenous agents.

Key Concept

Antimicrobial stewardship in Enterococcal bacteremia and pyelonephritis, specifically recognizing the pharmacokinetic limitations of nitrofurantoin.
Rate this question

Topics

Infectious Diseases

More questions from this topic